Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FBR086
MIFTS: 51

Fibrolamellar Carcinoma

Categories: Rare diseases, Liver diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Fibrolamellar Carcinoma

About this section

MalaCards integrated aliases for Fibrolamellar Carcinoma:

Name: Fibrolamellar Carcinoma 12 53
Fibrolamellar Hepatocellular Carcinoma 12 53 59 44 73
Eosinophilic Hepatocellular Carcinoma with Lamellar Fibrosis 53
Polygonal Cell Hepatocellular Carcinoma with Fibrous Stroma 53
Hepatocellular Carcinoma with Increased Stromal Fibrosis 53
Hepatocellular Carcinoma, Fibrolamellar 12
Hepatocellular Fibrolamellar Carcinoma 15
Eosinophilic Glassy Cell Hepatoma 53
Fibrolamellar Oncocytic Hepatoma 53
Oncocytic Hepatocellular Tumor 12
Fibrolamellar Hepatocarcinoma 59
Fl-Hcc 53
Fhcc 59

Characteristics:

Orphanet epidemiological data:

59
fibrolamellar hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adolescent,Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Liver diseases Endocrine diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:5015
MeSH 44 C537258
NCIt 50 C4131
SNOMED-CT 68 15619004 253018005
Orphanet 59 ORPHA401920
UMLS via Orphanet 74 C0334287
ICD10 via Orphanet 34 C22.0
UMLS 73 C0334287
Sources

Summaries for Fibrolamellar Carcinoma

About this section
NIH Rare Diseases : 53 Fibrolamellar carcinoma (FLC) is a rare form of liver cancer which is generally diagnosed in adolescents and young adults (before age 40). Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified. FLC is typically treated with surgical resection.

MalaCards based summary : Fibrolamellar Carcinoma, also known as fibrolamellar hepatocellular carcinoma, is related to mixed fibrolamellar hepatocellular carcinoma and ovary neuroendocrine neoplasm, and has symptoms including abdominal pain, fever and icterus. An important gene associated with Fibrolamellar Carcinoma is PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha), and among its related pathways/superpathways are Developmental Biology and Actin Nucleation by ARP-WASP Complex. The drugs Fulvestrant and Estradiol valerate have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and bone marrow, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 A hepatocellular carcinoma characterized microscopically by laminated fibrous layers interspersed between the tumour cells. The polygonal, deeply eosinophilic tumor cells arise in non-cirrhotic livers.

Wikipedia : 76 Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that... more...

Sources

Related Diseases for Fibrolamellar Carcinoma

About this section

Diseases related to Fibrolamellar Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 mixed fibrolamellar hepatocellular carcinoma 32.4 DNAJB1 PRKACA
2 ovary neuroendocrine neoplasm 10.6 KRT7 SYP
3 ovarian large-cell neuroendocrine carcinoma 10.6 KRT7 SYP
4 mucinous adenofibroma 10.6 KRT7 SYP
5 sensory organ benign neoplasm 10.6 KRT7 SYP
6 small cell carcinoma of the bladder 10.6 KRT7 SYP
7 middle ear adenoma 10.6 KRT7 SYP
8 pancreatic serous cystadenoma 10.6 KRT7 SYP
9 mucinous ovarian cystadenoma 10.6 KRT7 SYP
10 medulloepithelioma 10.6 KRT7 SYP
11 glycogen-rich clear cell breast carcinoma 10.6 KRT7 SYP
12 pulmonary sclerosing hemangioma 10.6 KRT7 SYP
13 seminal vesicle tumor 10.6 KRT7 SYP
14 ampulla of vater neoplasm 10.6 KRT7 SYP
15 sclerosing hemangioma 10.5 KRT7 SYP
16 proliferating trichilemmal cyst 10.5 KRT7 KRT8
17 endolymphatic sac tumor 10.5 KRT7 KRT8
18 mixed cell type cancer 10.5 KRT7 SYP
19 hidrocystoma 10.5 KRT7 KRT8
20 ovarian mucinous neoplasm 10.5 KRT7 SYP
21 cutaneous adenocystic carcinoma 10.5 KRT7 KRT8
22 apocrine sweat gland neoplasm 10.5 KRT7 KRT8
23 cystic teratoma 10.5 KRT7 SYP
24 nasal cavity cancer 10.5 KRT7 KRT8
25 horseshoe kidney 10.5 KRT7 SYP
26 brooke-spiegler syndrome 10.5 KRT7 KRT8
27 granulosa cell tumor of the ovary 10.4 KRT7 SYP
28 colon carcinoma in situ 10.4 ITGA1 ITGAV
29 large cell neuroendocrine carcinoma 10.4 KRT7 SYP
30 pleomorphic carcinoma 10.4 KRT7 KRT8
31 mucinous tubular and spindle renal cell carcinoma 10.4 KRT7 KRT8
32 lymphoepithelioma-like carcinoma 10.4 KRT7 KRT8
33 cystitis cystica 10.4 KRT7 SYP
34 prostate squamous cell carcinoma 10.4 KRT7 KRT8
35 nasal cavity squamous cell carcinoma 10.4 KRT7 KRT8
36 cystadenoma 10.3 KRT7 SYP
37 mammary paget's disease 10.3 KRT7 KRT8
38 cervical clear cell adenocarcinoma 10.3 KRT8 SYP
39 intraneural perineurioma 10.3 KRT7 KRT8
40 papillary ependymoma 10.3 KRT8 SYP
41 nephrogenic adenofibroma 10.2 KRT7 KRT8
42 secretory meningioma 10.2 KRT7 KRT8
43 hepatocellular carcinoma 10.2
44 sex cord-gonadal stromal tumor 10.2 KRT7 SYP
45 epithelioid sarcoma 10.1 KRT7 KRT8
46 spindle cell carcinoma 10.1 KRT7 SYP
47 cholangiocarcinoma 10.1
48 atypical choroid plexus papilloma 10.0 KRT7 KRT8 SYP
49 immune system organ benign neoplasm 10.0 KRT7 KRT8 SYP
50 thymus lipoma 10.0 KRT7 KRT8 SYP

Graphical network of the top 20 diseases related to Fibrolamellar Carcinoma:



Diseases related to Fibrolamellar Carcinoma
Sources

Symptoms & Phenotypes for Fibrolamellar Carcinoma

About this section

UMLS symptoms related to Fibrolamellar Carcinoma:


abdominal pain, fever, icterus, malaise

MGI Mouse Phenotypes related to Fibrolamellar Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.87 CCKBR FGFR1 ITGA1 ITGAV ITGB4 KRT8
2 growth/size/body region MP:0005378 9.76 PRKACA CCKBR FGFR1 ITGA1 ITGAV ITGB4
3 digestive/alimentary MP:0005381 9.73 CCKBR FGFR1 ITGAV ITGB4 KRT8 NR0B2
4 homeostasis/metabolism MP:0005376 9.61 CCKBR FGFR1 ITGA1 ITGAV ITGB4 KRT7
5 renal/urinary system MP:0005367 9.17 CCKBR FGFR1 ITGA1 ITGAV ITGB4 KRT7
Sources

Drugs & Therapeutics for Fibrolamellar Carcinoma

About this section

Drugs for Fibrolamellar Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
2 Estradiol valerate Approved, Investigational, Vet_approved Phase 2 979-32-8
3
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
4
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
5
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 2 28014-46-2
7
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
8
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
9
Everolimus Approved Phase 2 159351-69-6 6442177
10
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
11
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
12
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
13 Mitogens Phase 2,Phase 1
14 Albumin-Bound Paclitaxel Phase 2
15 Hormone Antagonists Phase 2
16 Hormones Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
18 Estradiol 17 beta-cypionate Phase 2
19 Estradiol 3-benzoate Phase 2
20 Estrogen Antagonists Phase 2
21 Estrogen Receptor Antagonists Phase 2
22 Estrogens Phase 2
23 Antimitotic Agents Phase 2
24 Antineoplastic Agents, Hormonal Phase 2
25 Antineoplastic Agents, Phytogenic Phase 2
26 Fertility Agents Phase 2
27 Steroid Synthesis Inhibitors Phase 2
28 Anti-Bacterial Agents Phase 2
29 Antibiotics, Antitubercular Phase 2
30 Immunosuppressive Agents Phase 2
31 Anti-Infective Agents Phase 2
32 Antifungal Agents Phase 2
33 Aromatase Inhibitors Phase 2
34 Angiogenesis Inhibitors Phase 2
35 Angiogenesis Modulating Agents Phase 2
36 Liver Extracts Phase 2
37 Cola Nutraceutical Phase 2
38 Endothelial Growth Factors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Neratinib HER Mutation Basket Study (SUMMIT) Recruiting NCT01953926 Phase 2 Neratinib;Paclitaxel;Fulvestrant;Trastuzumab
2 A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma Active, not recruiting NCT02234986 Phase 2 ENMD-2076
3 Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Active, not recruiting NCT01642186 Phase 2 everolimus;letrozole plus leuprolide;combination of everolimus, letrozole and leuprolide
4 Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma Terminated NCT01215565 Phase 2 Sutent
5 Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) Withdrawn NCT02702960 Phase 2 Cyclophosphamide;Mesna;Filgrastim;Tacrolimus;mycophenolate mofetil;Prednisone;Antithymocyte globulin;fludarabine
6 Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02159989 Phase 1 Sapanisertib
7 Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer Withdrawn NCT00899002

Search NIH Clinical Center for Fibrolamellar Carcinoma

Cochrane evidence based reviews: fibrolamellar hepatocellular carcinoma

Sources

Genetic Tests for Fibrolamellar Carcinoma

About this section
Sources

Anatomical Context for Fibrolamellar Carcinoma

About this section

MalaCards organs/tissues related to Fibrolamellar Carcinoma:

41
Liver, Endothelial, Bone Marrow, Bone, Testes
Sources

Publications for Fibrolamellar Carcinoma

About this section

Articles related to Fibrolamellar Carcinoma:

(show top 50) (show all 89)
# Title Authors Year
1
Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms. ( 29471565 )
2018
2
Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. ( 29473972 )
2018
3
Fibrolamellar Carcinoma: What Is New and Why It Matters. ( 29751881 )
2018
4
Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings. ( 28110996 )
2017
5
Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. ( 28304380 )
2017
6
Fibrolamellar Carcinoma in the Carney Complex: PRKAR1A Loss Instead of the Classic DNAJB1-PRKACA Fusion. ( 29222914 )
2017
7
An unusual case of jaundice: Biliary tumor thrombus in fibrolamellar hepatocellular carcinoma. ( 28531870 )
2017
8
Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation. ( 28486549 )
2017
9
CD47 is not Over-Expressed in Fibrolamellar Hepatocellular Carcinoma. ( 28801364 )
2017
10
Environmental exposures as a risk factor for fibrolamellar carcinoma. ( 28256571 )
2017
11
Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. ( 28862261 )
2017
12
Fibrolamellar hepatocellular carcinoma in ascitic fluid: A case report with cytohistological correlation. ( 27218242 )
2016
13
Duodenal Recurrence of Fibrolamellar Carcinoma 12 Years After Partial Hepatectomy and Adjuvant Chemotherapy. ( 27921059 )
2016
14
Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma. ( 26990031 )
2016
15
A genomic case study of mixed fibrolamellar hepatocellular carcinoma. ( 27029710 )
2016
16
Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma. ( 27027723 )
2016
17
Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. ( 27215576 )
2016
18
The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas. ( 26505878 )
2016
19
Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss. ( 27015136 )
2016
20
Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. ( 27456016 )
2016
21
Fibrolamellar hepatocellular carcinoma presenting as obstructive jaundice: uncommon presentation of a rare entity. ( 25866594 )
2015
22
Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. ( 25598114 )
2015
23
DNAJB1-PRKACA is specific for fibrolamellar carcinoma. ( 25698061 )
2015
24
Fibrolamellar carcinoma versus scirrhous hepatocellular carcinomaa88: diagnostic usefulness of CD68. ( 26712049 )
2015
25
Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases. ( 26017653 )
2015
26
FGFR1 and FGFR2 in fibrolamellar carcinoma. ( 26259677 )
2015
27
mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. ( 24925055 )
2015
28
Caroli's Syndrome with Incidental Fibrolamellar Carcinoma on Liver Explant. ( 25990596 )
2015
29
Liver cancer: A model of fibrolamellar carcinoma. ( 26503883 )
2015
30
Unique genomic profile of fibrolamellar hepatocellular carcinoma. ( 25557953 )
2015
31
Genomic analysis of fibrolamellar hepatocellular carcinoma. ( 25122662 )
2015
32
Treatment of Paraneoplastic Hyperammonemia in Fibrolamellar Hepatocellular Carcinoma With Oral Sodium Phenylbutyrate. ( 25891666 )
2015
33
Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. ( 24844420 )
2014
34
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. ( 24578576 )
2014
35
Surgical treatment of fibrolamellar hepatocellular carcinoma: an underestimated malignant tumor? ( 25475864 )
2014
36
Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. ( 24443104 )
2014
37
Fibrolamellar hepatocellular carcinoma mimicking ornithine transcarbamylase deficiency. ( 24997132 )
2014
38
Fibrolamellar carcinoma in a 62 year-old patient with human immunodeficiency virus infection. ( 24908574 )
2014
39
CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients. ( 24896196 )
2014
40
Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. ( 24315886 )
2014
41
Better 5-year survival of fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: still too close to call. ( 24385596 )
2014
42
Typical fibrolamellar hepatocellular carcinoma in a Japanese boy: report of a case. ( 23828653 )
2014
43
Fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: better 5-year survival or artifactual result of research methodology? ( 24234001 )
2013
44
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. ( 23505572 )
2013
45
Combined hepatocellular carcinoma and fibrolamellar carcinoma presenting as two adjacent separate lesions in a young boy: first case report from Asia. ( 25374712 )
2013
46
Response to fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: better 5-year survival or artefactual result of research methodology? ( 24287277 )
2013
47
Cytologic features of fibrolamellar carcinoma with mucin production: A rare variant of combined hepatocellular-cholangiocarcinoma. ( 23008149 )
2012
48
Fibrolamellar carcinoma: 2012 update. ( 24278737 )
2012
49
Loss of the orphan nuclear receptor SHP is more pronounced in fibrolamellar carcinoma than in typical hepatocellular carcinoma. ( 22292081 )
2012
50
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. ( 22415897 )
2012
Sources

Variations for Fibrolamellar Carcinoma

About this section

Cosmic variations for Fibrolamellar Carcinoma:

9
(show top 50) (show all 3335)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 28
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 28
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 28
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 28
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 28
6 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 28
7 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 28
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 28
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 28
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 28
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 28
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 28
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 28
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 28
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 28
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 28
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 28
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 28
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 28
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 28
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 28
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 28
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 28
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 28
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 28
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 28
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 28
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 28
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 28
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 28
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 28
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 28
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 28
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 28
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 28
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 28
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 28
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 28
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 28
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 28
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 28
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 28
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 28
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 28
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 28
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 28
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 28
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 28
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 28
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 28
Sources

Expression for Fibrolamellar Carcinoma

About this section
Search GEO for disease gene expression data for Fibrolamellar Carcinoma.
Sources

Pathways for Fibrolamellar Carcinoma

About this section

Pathways related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 66
Show member pathways
 13.17 FGFR1 ITGA1 ITGAV KRT7 KRT8 PRKACA
2
Actin Nucleation by ARP-WASP Complex 64
Show member pathways
 12.69 FGFR1 ITGA1 ITGAV ITGB4
3
Sertoli-Sertoli Cell Junction Dynamics 64
Show member pathways
 12.68 ITGA1 ITGAV ITGB4 PRKACA
4
MAPK-Erk Pathway 67
Show member pathways
 12.59 ITGA1 ITGAV ITGB4 PRKACA
5
PI3K-Akt signaling pathway 37
Show member pathways
 12.59 FGFR1 ITGA1 ITGAV ITGB4 PRKACA
6
Beta-Adrenergic Signaling 64
Show member pathways
 12.55 ITGA1 ITGAV ITGB4 PRKACA
7
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.39 FGFR1 ITGA1 ITGAV ITGB4 PRKACA
8
Regulation of actin cytoskeleton 37 1
12.29 FGFR1 ITGA1 ITGAV ITGB4
9
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 37
Show member pathways
 12.19 ITGA1 ITGAV ITGB4
10
MET promotes cell motility 66
Show member pathways
 12.13 ITGA1 ITGAV ITGB4
11
Proteoglycans in cancer 37
12.07 FGFR1 ITGAV PRKACA
12
VEGF Signaling Pathway 67 61
Show member pathways
 12 FGFR1 ITGA1 ITGAV
13
ECM-receptor interaction 37
Show member pathways
 11.88 ITGA1 ITGAV ITGB4
14
Blood-Brain Barrier and Immune Cell Transmigration: Pathways Overview 65
Show member pathways
 11.82 ITGA1 ITGAV ITGB4
15
L1CAM interactions 66
Show member pathways
 11.73 FGFR1 ITGA1 ITGAV
16
AKT Signaling Pathway 67
11.61 FGFR1 ITGA1 ITGAV ITGB4
17
Phagocytosis of Microbes 64
11.51 ITGA1 ITGAV ITGB4
18
Dilated cardiomyopathy (DCM) 37
Show member pathways
 11.49 ITGA1 ITGAV ITGB4 PRKACA
19
G-protein signaling_Regulation of RAC1 activity 22
11.37 ITGA1 ITGAV ITGB4
20
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.37 ITGAV ITGB4 KRT8
21
Cytoskeleton remodeling_RalA regulation pathway 22
11.3 ITGA1 ITGAV ITGB4
22
Signal transduction by L1 66
10.86 FGFR1 ITGAV
23
Cell adhesion_Endothelial cell contacts by non-junctional mechanisms 22
10.4 ITGA1 ITGAV ITGB4
Sources

GO Terms for Fibrolamellar Carcinoma

About this section

Cellular components related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.5 DNAJB1 ITGA1 ITGAV ITGB4 KRT7 KRT8
2 integrin complex GO:0008305 8.8 ITGA1 ITGAV ITGB4

Biological processes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.33 ITGA1 ITGAV ITGB4
2 digestive tract development GO:0048565 9.26 CCKBR ITGB4
3 cell-matrix adhesion GO:0007160 9.13 ITGA1 ITGAV ITGB4
4 integrin-mediated signaling pathway GO:0007229 8.8 ITGA1 ITGAV ITGB4

Molecular functions related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor binding GO:0017134 9.16 FGFR1 ITGAV
2 insulin-like growth factor I binding GO:0031994 8.96 ITGAV ITGB4
3 neuregulin binding GO:0038132 8.62 ITGAV ITGB4
Sources

Sources for Fibrolamellar Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....